The long-term trend of the EPS is an important number as it indicates the present value of Xenon Pharmaceuticals. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -97.40% over the last twelve months. The long-term trend in EPS shows how well the management of Xenon Pharmaceuticals is adding value for shareholders.



Xenon Pharmaceuticals trades as part of the healthcare sector and biotechnology industry. The company CEO is Simon Pimstone. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.

Previous Intraday Performance:

The XENE shares had a previous change of -2.28% which opened at 7.89 and closed at 7.72. It moved to an intraday high of 7.96 and a low of 7.61.

SeekingAlpha:  Vertex: Shareholders Might Have Reason To Breathe More Easily

Historical Performance:

Over the last five trading days, XENE shares returned -3.74% and in the past 30 trading days it returned -2.15%. Over three months, it changed -4.57%. In one year it has changed 107.25% and within that year its 52-week high was 15.92 and its 52-week low was 3.60. XENE stock is 114.44% above its 52 Week Low.

Our calculations result in a 200 day moving average of 9.13 and a 50 day moving average of 7.44. Right now, XENE stock is trading -15.42% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Vertex: Shareholders Might Have Reason To Breathe More Easily

Liquidity:

The company has a market cap of $194.9m with 25.2m shares outstanding and a float of 24.5m shares. Trading volume was 39,014 shares and has experienced an average volume of 69,987 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Xenon Pharmaceuticals was -1.72 which ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.37.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.33
06-30-2018:  -0.45
03-31-2018:  -0.21
12-31-2017:  -0.45

Indicators Also to Watch:

Based on the latest filings, there is 83.10% of institutional ownership.



I calculated the beta to be 1.68

SeekingAlpha:  Daily Insider Ratings Round Up – Jan. 14, 2019

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -44.34%, return on assets is -35.72% and price-to-book is 1.98.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here